Global Launch Delays in the Life Sciences Industry – Impact on Patients & Revenue

Delays in global launches keep life-saving medicines from the patients who need them most, while companies miss out on vital revenue during the patent-protected period.

Today, reaching blockbuster status requires a proactive, agile approach to launch strategy, making global market access essential.

Each day a launch is delayed represents a lost opportunity for patients awaiting innovative treatments and companies seeing revenue potential slip away.

Building efficient global launch operations beyond the US and the top 10 markets is now imperative for life sciences companies to create blockbuster franchises. It’s about more than expanding reach; it’s about ensuring timely access for patients worldwide.

Unipr empowers commercial teams to adapt swiftly to market-specific dynamics and effectively respond to regulatory and competitive pressures.

By allocating resources in real-time and preemptively aligning with country guidelines, Unipr enhances agility, enabling smoother and more responsive market entry.

What can companies do differently to avoid delays?

1. Anticipate Challenges with Predictive AI – Predictive AI can help identify potential roadblocks, allowing companies to assess the impact of each delay and make proactive adjustments.

2. Scenario Planning for Agility – Developing shadow scenario plans enables teams to pivot quickly, redirect resources, and execute alternative strategies in response to regulatory and market shifts.

The ultimate goal of life sciences is to transform lives globally; with an adaptable launch strategy, innovative medicines can reach patients faster.